BioCentury
ARTICLE | Company News

Horizon Pharma sales and marketing update

December 10, 2012 8:00 AM UTC

Horizon Pharma launched Rayos prednisone delayed-release tablets in the U.S., with an initial focus on treating rheumatic disease including rheumatoid arthritis and polymyalgia rheumatica. The wholesale acquisition cost (WAC) is $7 per day for a once-daily 5 mg tablet. FDA approved the delayed-release oral formulation of low-dose prednisone in July to treat RA, polymyalgia rheumatica, psoriatic arthritis and ankylosing spondylitis, as well as asthma and chronic obstructive pulmonary disease (COPD). The product is also indicated for dermatologic, gastrointestinal, hematologic, pulmonary and infectious diseases as well as allergic, endocrine, neoplastic, nervous system, ophthalmic, renal conditions and conditions related to organ transplantation. The company said it would promote the drug to about 1,000 rheumatologists using 13 sales specialists and will target January for a "full-launch" using its entire sales staff of about 150 (see BioCentury, July 30). ...